Devonian Health Group Inc. (DVHGF)
USD 0.14
(0.0%)
USD 0.14
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 19.17 Million CAD | -11.16% |
| 2022 | 21.58 Million CAD | 47.77% |
| 2021 | 14.6 Million CAD | -12.51% |
| 2020 | 16.69 Million CAD | -2.63% |
| 2019 | 17.14 Million CAD | -10.49% |
| 2018 | 19.15 Million CAD | 65.75% |
| 2017 | 11.55 Million CAD | 14.73% |
| 2016 | 10.07 Million CAD | 3866.32% |
| 2015 | 254 Thousand CAD | 82.76% |
| 2014 | 138.97 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 18.98 Million CAD | -0.98% |
| 2024 Q2 | 17.22 Million CAD | -9.26% |
| 2024 Q3 | 25.34 Million CAD | 47.1% |
| 2023 Q1 | 19.93 Million CAD | -7.63% |
| 2023 Q2 | 19.72 Million CAD | -1.07% |
| 2023 FY | 19.17 Million CAD | -11.16% |
| 2023 Q3 | 18.75 Million CAD | -4.93% |
| 2023 Q4 | 19.17 Million CAD | 2.26% |
| 2022 Q2 | 23.87 Million CAD | 60.15% |
| 2022 Q4 | 21.58 Million CAD | -7.83% |
| 2022 FY | 21.58 Million CAD | 47.77% |
| 2022 Q1 | 14.91 Million CAD | 2.07% |
| 2022 Q3 | 23.42 Million CAD | -1.92% |
| 2021 Q1 | 15.59 Million CAD | -6.59% |
| 2021 FY | 14.6 Million CAD | -12.51% |
| 2021 Q4 | 14.6 Million CAD | -2.92% |
| 2021 Q3 | 15.04 Million CAD | -4.94% |
| 2021 Q2 | 15.82 Million CAD | 1.49% |
| 2020 Q3 | 17.82 Million CAD | 6.71% |
| 2020 Q4 | 16.69 Million CAD | -6.36% |
| 2020 Q2 | 16.7 Million CAD | -5.66% |
| 2020 FY | 16.69 Million CAD | -2.63% |
| 2020 Q1 | 17.71 Million CAD | 3.29% |
| 2019 Q4 | 17.14 Million CAD | -5.24% |
| 2019 Q2 | 20.46 Million CAD | 2.35% |
| 2019 FY | 17.14 Million CAD | -10.49% |
| 2019 Q1 | 19.99 Million CAD | 4.37% |
| 2019 Q3 | 18.09 Million CAD | -11.58% |
| 2018 Q3 | 20.13 Million CAD | 96.64% |
| 2018 Q4 | 19.15 Million CAD | -4.85% |
| 2018 FY | 19.15 Million CAD | 65.75% |
| 2018 Q2 | 10.23 Million CAD | -6.52% |
| 2018 Q1 | 10.95 Million CAD | -5.23% |
| 2017 FY | 11.55 Million CAD | 14.73% |
| 2017 Q4 | 11.55 Million CAD | 13.6% |
| 2017 Q3 | 10.17 Million CAD | 12342.25% |
| 2017 Q1 | 85.97 Thousand CAD | -1.77% |
| 2017 Q2 | 81.77 Thousand CAD | -4.88% |
| 2016 Q3 | 134.34 Thousand CAD | -0.92% |
| 2016 FY | 10.07 Million CAD | 3866.32% |
| 2016 Q2 | 135.59 Thousand CAD | -31.38% |
| 2016 Q1 | 197.62 Thousand CAD | -22.2% |
| 2016 Q4 | 87.52 Thousand CAD | -34.85% |
| 2015 Q1 | 283.52 Thousand CAD | 0.0% |
| 2015 Q3 | 252.74 Thousand CAD | 0.0% |
| 2015 FY | 254 Thousand CAD | 82.76% |
| 2015 Q4 | 254 Thousand CAD | 0.5% |
| 2014 FY | 138.97 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -830093.853% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 85.272% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -2388.5% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -3373.426% |
| Qrons Inc. | 420.00 USD | -4565966.19% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -5323.234% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -81.708% |
| BioStem Technologies, Inc. | 14.56 Million USD | -31.711% |
| Skye Bioscience, Inc. | 11.94 Million USD | -60.61% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -3890.677% |
| Rebus Holdings, Inc. | 5000.00 USD | -383449.56% |
| CSL Limited | 38.02 Billion USD | 99.95% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 31.372% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 63.611% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -2689.508% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -879.348% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 50.633% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -165.625% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -25016.534% |
| SQZ Biotechnologies Company | 107.18 Million USD | 82.108% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1239.179% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -26401.041% |
| Mesoblast Limited | 667.9 Million USD | 97.129% |
| Marizyme, Inc. | 22.01 Million USD | 12.889% |
| Genus plc | 1.02 Billion USD | 98.136% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1311.818% |
| Pharming Group N.V. | 462.85 Million USD | 95.857% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -478.853% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -3742.882% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -2958.609% |
| ContraFect Corporation | 20.67 Million USD | 7.261% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -4812.692% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -4917.957% |
| IMV Inc. | 31.33 Million USD | 38.796% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -362.551% |
| MultiCell Technologies, Inc. | 126.22 USD | -15193591.966% |
| ONE Bio Corp. | 70.08 Million USD | 72.637% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1940.832% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 85.077% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -4342.172% |
| Q BioMed Inc. | 3.51 Million USD | -445.509% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 45.486% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -7239.903% |
| Biomind Labs Inc. | 73.81 Thousand USD | -25879.054% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 95.703% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1223.641% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 36.107% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -598.293% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -636.69% |
| GB Sciences, Inc. | 103.44 Thousand USD | -18439.353% |
| Alpha Cognition Inc. | 2.45 Million USD | -682.062% |
| HST Global, Inc. | 1526.00 USD | -1256615.465% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1841.105% |
| Halberd Corporation | 10.13 Thousand USD | -189195.015% |
| Enzolytics Inc. | 361.7 Million USD | 94.698% |
| Agentix Corp. | 261.39 Thousand USD | -7236.674% |
| Resverlogix Corp. | 8.11 Million USD | -136.321% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -921.23% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.578% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 59.797% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -2898.092% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -84081.897% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -114.294% |
| AVAX Technologies, Inc. | 7.37 Million USD | -159.958% |
| Zenith Capital Corp. | 7410.00 USD | -258705.371% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.434% |
| Ember Therapeutics, Inc. | 184.00 USD | -10422442.391% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -5859.329% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -7237.46% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1966.625% |
| Kadimastem Ltd | 2.3 Million USD | -732.327% |
| Helix BioMedix, Inc. | 3.02 Million USD | -533.948% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -33489.305% |
| LadRx Corporation | 2.3 Million USD | -730.956% |
| Cell Source, Inc. | 195.17 Thousand USD | -9725.987% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -5323.234% |
| NovAccess Global Inc. | 62.24 Thousand USD | -30708.183% |
| Affymax, Inc. | 7.44 Million USD | -157.658% |
| Itoco Inc. | 1.4 Million USD | -1269.749% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -19948.17% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -17991.96% |
| Mobile Lads Corp. | 52.00 USD | -36879665.385% |
| CytoDyn Inc. | 11.13 Million USD | -72.212% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -13313.45% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -107156.588% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -4875.077% |
| SYBLEU INC | 330.46 Thousand USD | -5703.127% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -4584.037% |
| International Stem Cell Corporation | 5.39 Million USD | -255.797% |
| Bioxytran, Inc. | 137.63 Thousand USD | -13833.273% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -27.834% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -15.673% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -24175.289% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -2117.878% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -155.121% |
| Neutra Corp. | 2851.00 USD | -672557.945% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 40.821% |
| PureTech Health plc | 693.97 Million USD | 97.237% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -137.607% |
| IXICO plc | 15.84 Million USD | -21.04% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -131.556% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 81.439% |
| CSL Limited | 38.02 Billion USD | 99.95% |
| Cellectis S.A. | 333.99 Million USD | 94.258% |